The current standard for muscle-invasive bladder cancer (BC) patients is cisplatin-based neoadjuvant chemotherapy. However, the prognosis of the cancer patients has not been substantially improved and several different mechanisms could be involved. Previously, we showed that BC cells promote autophagy as a resistant mechanism upon cisplatin treatment. Cancer immunoresistance and immune escape are major obstacle in chemotherapy. However, the effects of cisplatin on the immune responses of BC cells are note clear. In the present studies, we investigate the expression of immunoresistance molecular PD-L1 on cisplatin-treated 5637 and T24 cells.
INTRODUCTION AND OBJECTIVES:
The current standard for muscle-invasive bladder cancer (BC) patients is cisplatin-based neoadjuvant chemotherapy. However, the prognosis of the cancer patients has not been substantially improved and several different mechanisms could be involved. Previously, we showed that BC cells promote autophagy as a resistant mechanism upon cisplatin treatment. Cancer immunoresistance and immune escape are major obstacle in chemotherapy. However, the effects of cisplatin on the immune responses of BC cells are note clear. In the present studies, we investigate the expression of immunoresistance molecular PD-L1 on cisplatin-treated 5637 and T24 cells.
METHODS: Human immortalized urothelial (SV-Huc-1) and bladder cancer (5637 and T24) cell lines were used in this study. The expression of PD-L1 mRNA and protein in control or cisplatin-treated cells were detected by quantitative RT-PCR and Western blot. PD-L1 knockdown in cisplatin treated cells was conducted using lenti-viral based shRNA. Cell viability in cisplatin-treated cells with or without PD-L1 knockdown was monitored by tetrazolium salt WST-1. Cell signaling pathways, including AKT, ERK, MAPK and JNK, were detected by Western blot. PD98059 and Baf A1 were used as inhibitors for MAPK and autophagy, respectively.
RESULTS: Up-regulation of PD-L1 expression was detected in 5637 and T24 cells treated with various concentrations of cisplatin. Increased levels of ERK, AKT, and JNK phosphorylation were observed in cisplatin-treated human BC cells, but only pretreatment of PD98059 in cisplatin-treated cells attenuated the expression of PD-L1, suggesting that cisplatin-induced PD-L1 expression in BC cells is dependent of ERK pathway. In addition, inhibition of autophagy using Baf A1 did not suppressed cisplatin-induced PD-L1, indicating cisplatin not only induces the intrinsic protective autophagy but up-regulates immune checkpoint, PD-L1, as an immune escape pro-survival mechanism in human bladder cancer cells.
CONCLUSIONS: Cisplatin induces PD-L1 in human BC cells, suggesting an immune escape mechanism other than intrinsic protective autophagy. Targeting ERK pathway could be considered as therapeutic options in cisplatin resistant.
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MP58-17 THE CONTRIBUTION OF HGF-MET-MMP1 SIGNALING IN BLADDER CANCER INVASION, AND MET INHIBITOR AS A POTENTIAL THERAPEUTIC OPTION FOR INVASIVE BLADDER CANCER
Tomoya Fukawa*, Kei Daizumoto, Tomoharu Fukumori, Masayuki Takahashi, Hiro-omi Kanayama, Tokushima, Japan INTRODUCTION AND OBJECTIVES: Muscle-invasive bladder cancer (MIBC) has an especially poor prognosis, and clarification of the mechanism of MIBC invasion is urgent to discover appropriate treatment strategies and to improve the prognosis of patients with MIBC. Our previous report showed that co-culture of bladder cancer cells with mesenchymal cells which highly expressed HGF stimulated the invasion ability of bladder cancer cells. The aim of this study was to elucidate the underlying mechanisms of the increased invasion ability of bladder cancer cells by co-culture with mesenchymal cells, clarify the contribution of HGF-MET signaling pathway to bladder cancer progression and find a new therapeutic option for MIBC.
METHODS: We analyzed the expression of MET in the bladder cancer cell lines by Western blotting. Using the cell lines which highly expressed MET, we examined the effects of Cabozantinib on their proliferation and invasion abilities by using MTT and Matrigel invasion assays. To investigate the biological function of HGF-MET signaling, we analyzed gene expression profiles of bladder cancer cells that were cultivated with/without the effects of the MET inhibitor, Cabozantinib (XL184). We also examined the effects of MMP-1 depletion on invasion ability to clarify the importance of HGF-MET-MMP1 signaling in bladder cancer invasion. To verify our results with clinical samples, we checked the relationship between the expression of MET and MMP-1 by using TCGA data.
RESULTS: The expression of MET was high in four of five bladder cancer cell lines, and 5637 and T24 cells showed especially high protein expression of MET. The treatment with HGF stimulated cell proliferation and invasion of these cancer cells, whereas Cabozantinib inhibited those effects induced by HGF stimulation. To clarify the underlying mechanisms, we analyzed gene expression profiles by using microarray and revealed that the expression of MMP-1 was significantly elevated by HGF addition. We also confirmed that Cabozantinib suppressed the expression of MMP-1 which was induced by HGF addition in bladder cancer cells. Consistent with these results, we found the strong association between the expression of MET and MMP1 by using TCGA data. Furthermore, the depletion of MMP-1 dramatically suppressed the invasion ability of bladder cancer cells, suggesting that HGF contributes bladder cancer invasion by regulating the expressions of MMP-1 CONCLUSIONS: The results of this study suggested that the blockade of HGF-MET-MMP1 signaling could be a potential therapeutic option and Cabozantinib is one of the potential molecules for the treatment of MIBC. Our aim was to compare the inter-observer variability (reproducibility) of both classifications and to explore which histologic criteria cause this variability. Additionally, the prognostic value of both classifications was assessed.
METHODS: 328 NMIBC tissues of 232 patients were reviewed by three uropathologists in a blinded manner. Grade according to both classifications (WHO1973 and WHO2004), histologic criteria of both classifications that define these grades and T-category were assessed. Inter-observer variability was analyzed using weighted Fleiss k. The individual criteria scores and their association with grade was analyzed using the c2-test. Time-to-recurrence and time-to-progression were analysed using log-rank test and Coxregression. Vol. 199, No. 4S, Supplement, Sunday, May 20, 2018 THE JOURNAL OF UROLOGY â e779
